Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

323
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

203
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
203
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

240
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
240
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

223
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Atopic Disease in Pediatric Patients with Hypermobile Ehlers-Danlos Syndrome.

Pediatric allergy, immunology, and pulmonology·2026
Same author

Understanding imposter phenomenon in genetic counselors: Impact and strategies for mitigation.

Journal of genetic counseling·2026
Same author

Artificial Intelligence-Ready Doctor of Nursing Practice Education: A Competency-Based Approach.

Journal of doctoral nursing practice·2026
Same author

Centering Reproductive and Migrant Justice: Dismantling Inequities in Newcomer Pregnancy Care.

Obstetrics and gynecology·2026
Same author

Prognostic significance of clinicopathological parameters, margin width and locoregional recurrences on outcome of primary and radiation associated breast angiosarcoma- results from a large UK sarcoma regional service.

Breast cancer research : BCR·2026
Same author

PertSpectra: Interpretable Matrix Factorization for Predicting Functional Impact of Genetic Perturbation Experiments.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing·2026

Related Experiment Video

Updated: Jun 26, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.1K

Improving Pneumococcal Vaccination Rates in Immunosuppressed Pediatric Patients with Rheumatic Disease.

Julia G Harris1,2, Jordan T Jones1,2, Leslie Favier1,2

  • 1From the Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Mo.

Pediatric Quality & Safety
|May 16, 2024
PubMed
Summary
This summary is machine-generated.

Immunosuppressed patients with rheumatic diseases are at high risk for pneumococcal disease. A quality improvement project successfully increased pneumococcal vaccination rates, significantly reducing this risk.

More Related Videos

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

12.2K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.6K

Related Experiment Videos

Last Updated: Jun 26, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.1K
Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

12.2K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.6K

Area of Science:

  • Rheumatology
  • Immunology
  • Infectious Disease Prevention

Background:

  • Patients with rheumatic diseases often experience immunosuppression, increasing their risk of invasive pneumococcal disease.
  • Systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are key conditions associated with this heightened risk.

Purpose of the Study:

  • To implement a quality improvement project to increase pneumococcal vaccination rates in high-risk, immunosuppressed patients.
  • Aim 1: Increase pneumococcal vaccination in systemic lupus erythematosus and mixed connective tissue disease patients from 9.6% to 80% within one year.
  • Aim 2: Increase vaccination in immunosuppressed patients with systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis from 62.6% to 80% within one year.

Main Methods:

  • Utilized a quality improvement framework with interventions including an immunization algorithm, patient reporting, education, reminders, and pre-visit planning.
  • Monitored vaccination status for 13-valent pneumococcal conjugated vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23).
  • Defined the primary outcome as being fully up-to-date on both PCV13 and PPSV23 vaccinations.

Main Results:

  • Phase 1 saw a significant increase in combined pneumococcal vaccination rates from 9.6% to 91.1%, with sustained high rates.
  • Phase 2 demonstrated substantial improvements: PCV13 rates rose from 68.8% to 93.4%, PPSV23 from 65.2% to 88.5%, and combined rates from 62.6% to 86.5%.

Conclusions:

  • Quality improvement initiatives effectively increased and sustained pneumococcal vaccination coverage in high-risk, immunosuppressed patient populations.
  • These efforts are crucial for mitigating the incidence of invasive pneumococcal disease in vulnerable individuals.
  • Continued prioritization of vaccination programs is essential for patient safety and disease prevention.